A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion - PubMed (original) (raw)
. 2008 Oct 15;100(20):1464-76.
doi: 10.1093/jnci/djn325. Epub 2008 Oct 7.
Ioannis Psallidas, Ardiana Moustaki, Charalampos Moschos, Androniki Kollintza, Sophia Karabela, Ilias Porfyridis, Spyridoula Vassiliou, Marilena Karatza, Zongmin Zhou, Myungsoo Joo, Timothy S Blackwell, Charis Roussos, Daniel Graf, Ioannis Kalomenidis
Affiliations
- PMID: 18840818
- DOI: 10.1093/jnci/djn325
A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion
Georgios T Stathopoulos et al. J Natl Cancer Inst. 2008.
Abstract
Background: Tumor cells in malignant pleural effusions (MPEs) are an important source of monocyte chemoattractant protein (MCP)-1. However, the role of tumor-derived MCP-1 in the pathogenesis and progression of MPE has not been determined.
Methods: B16 mouse skin melanoma cells, which are deficient in MCP-1 expression, and mouse Lewis lung cancer (LLC) cells, which express high levels of MCP-1, were engineered to stably express MCP-1 and short hairpin RNAs (shRNAs) targeting the MCP-1 transcript, respectively. Cells were injected into the pleural cavities of syngeneic immunocompetent mice, and MPE volume and pleural tumors were quantified at necropsy (day 14). MCP-1 and other mediators were determined by cytometric bead array and enzyme-linked immunosorbent assay, and mononuclear and endothelial cells were identified by immunolabeling of F4/80 and factor VIII-related antigen respectively. Mouse survival was assessed using Kaplan-Meier analysis. Vascular permeability in mice with MPE was assessed using albumin-binding Evans blue. Statistical tests were two-sided.
Results: LLC cells expressing shRNA against MCP-1 elaborated less than 5% of the MCP-1 level in cells expressing nonspecific shRNA (control cells), and intrapleural delivery of these cells resulted in less MPE (mean MPE volume = 86 and 585 muL, respectively; difference = 499 muL; 95% confidence interval [CI] = 331 to 669 muL; P < .001), reduced MCP-1 levels in the pleural fluid, and lower mortality than when control cells were delivered. Overexpression of MCP-1 in intrapleurally injected B16 melanoma cells led to increased MPE and reduced survival. In mice with MPE, MCP-1 was a potent inducer of vascular permeability, mononuclear recruitment, and, in pleural tumors, of angiogenesis.
Conclusion: MCP-1 produced by tumor cells is an important determinant of their capacity to induce the formation of MPE and may be a useful target for the treatment of malignant pleural disease.
Similar articles
- Tumor necrosis factor-alpha promotes malignant pleural effusion.
Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, Pitsinos EN, Vassiliou S, Karatza M, Papiris SA, Graf D, Orphanidou D, Light RW, Roussos C, Blackwell TS, Kalomenidis I. Stathopoulos GT, et al. Cancer Res. 2007 Oct 15;67(20):9825-34. doi: 10.1158/0008-5472.CAN-07-1064. Cancer Res. 2007. PMID: 17942913 - Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.
Cui R, Takahashi F, Ohashi R, Yoshioka M, Gu T, Tajima K, Unnoura T, Iwakami S, Hirama M, Ishiwata T, Iwase A, Takahashi K. Cui R, et al. Lung Cancer. 2009 Mar;63(3):368-74. doi: 10.1016/j.lungcan.2008.06.020. Epub 2008 Aug 26. Lung Cancer. 2009. PMID: 18752867 - A sulindac analogue is effective against malignant pleural effusion in mice.
Moschos C, Psallidas I, Cottin T, Kollintza A, Papiris S, Roussos C, Stathopoulos GT, Giannis A, Kalomenidis I. Moschos C, et al. Lung Cancer. 2011 Aug;73(2):171-5. doi: 10.1016/j.lungcan.2010.12.005. Epub 2011 Jan 11. Lung Cancer. 2011. PMID: 21227533 - Animal models of malignant pleural effusion.
Stathopoulos GT, Kalomenidis I. Stathopoulos GT, et al. Curr Opin Pulm Med. 2009 Jul;15(4):343-52. doi: 10.1097/MCP.0b013e32832af07c. Curr Opin Pulm Med. 2009. PMID: 19387350 Review. - Diagnosis and management of malignant pleural effusions.
Heffner JE. Heffner JE. Respirology. 2008 Jan;13(1):5-20. doi: 10.1111/j.1440-1843.2007.01154.x. Respirology. 2008. PMID: 18197908 Review.
Cited by
- Monocyte chemoattractant protein-1/CCL2 produced by stromal cells promotes lung metastasis of 4T1 murine breast cancer cells.
Yoshimura T, Howard OM, Ito T, Kuwabara M, Matsukawa A, Chen K, Liu Y, Liu M, Oppenheim JJ, Wang JM. Yoshimura T, et al. PLoS One. 2013;8(3):e58791. doi: 10.1371/journal.pone.0058791. Epub 2013 Mar 18. PLoS One. 2013. PMID: 23527025 Free PMC article. - Switching off malignant pleural effusion formation-fantasy or future?
Spella M, Giannou AD, Stathopoulos GT. Spella M, et al. J Thorac Dis. 2015 Jun;7(6):1009-20. doi: 10.3978/j.issn.2072-1439.2015.05.20. J Thorac Dis. 2015. PMID: 26150914 Free PMC article. Review. - The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.
Bradshaw M, Mansfield A, Peikert T. Bradshaw M, et al. Curr Oncol Rep. 2013 Jun;15(3):207-16. doi: 10.1007/s11912-013-0315-7. Curr Oncol Rep. 2013. PMID: 23568600 Free PMC article. Review. - Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients.
Ruan X, Sun Y, Wang W, Ye J, Zhang D, Gong Z, Yang M. Ruan X, et al. Oncol Lett. 2020 May;19(5):3495-3505. doi: 10.3892/ol.2020.11446. Epub 2020 Mar 5. Oncol Lett. 2020. PMID: 32269623 Free PMC article. - Diagnostic and prognostic significance of lysophosphatidic acid in malignant pleural effusions.
Bai CQ, Yao YW, Liu CH, Zhang H, Xu XB, Zeng JL, Liang WJ, Yang W, Song Y. Bai CQ, et al. J Thorac Dis. 2014 May;6(5):483-90. doi: 10.3978/j.issn.2072-1439.2014.02.14. J Thorac Dis. 2014. PMID: 24822107 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous